Semler Scientific Inc. (SMLR): Price and Financial Metrics


Semler Scientific Inc. (SMLR): $118.20

0.20 (+0.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SMLR POWR Grades


  • SMLR scores best on the Sentiment dimension, with a Sentiment rank ahead of 99.01% of US stocks.
  • The strongest trend for SMLR is in Growth, which has been heading up over the past 31 weeks.
  • SMLR ranks lowest in Value; there it ranks in the 34th percentile.

SMLR Stock Summary

  • The price/operating cash flow metric for Semler Scientific Inc is higher than 90.68% of stocks in our set with a positive cash flow.
  • The ratio of debt to operating expenses for Semler Scientific Inc is higher than it is for about just 0.53% of US stocks.
  • With a price/sales ratio of 18.72, Semler Scientific Inc has a higher such ratio than 89.33% of stocks in our set.
  • Stocks that are quantitatively similar to SMLR, based on their financial statements, market capitalization, and price volatility, are AEO, EQX, EYE, SIG, and LJPC.
  • SMLR's SEC filings can be seen here. And to visit Semler Scientific Inc's official web site, go to www.semlerscientific.com.

SMLR Valuation Summary

  • SMLR's price/earnings ratio is 49.8; this is 46.47% higher than that of the median Healthcare stock.
  • Over the past 90 months, SMLR's EV/EBIT ratio has gone up 55.9.
  • SMLR's price/earnings ratio has moved up 64.2 over the prior 90 months.

Below are key valuation metrics over time for SMLR.

Stock Date P/S P/B P/E EV/EBIT
SMLR 2020-03-11 9.0 22.5 19.5 26.8
SMLR 2020-03-05 11.6 24.2 25.1 36.6
SMLR 2019-07-24 13.3 51.4 51.4 48.9
SMLR 2018-12-28 10.5 89.7 53.4 48.4
SMLR 2016-03-01 1.8 -11.7 -1.5 -1.4
SMLR 2014-09-23 6.6 2.6 -6.8 -4.1

SMLR Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at 678.21%.
  • Its 2 year price growth rate is now at 355.88%.
  • Its year over year net income to common stockholders growth rate is now at 1.93%.
Over the past 49 months, SMLR's revenue has gone up $34,367,000.

The table below shows SMLR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 42.356 16.281 16.211
2020-12-31 38.603 15.417 14.007
2020-09-30 35.681 13.235 11.447
2020-06-30 33.856 14.427 14.36
2020-03-31 35.436 14.767 15.904
2019-12-31 32.767 12.728 15.084

SMLR Stock Price Chart Interactive Chart >

Price chart for SMLR

SMLR Price/Volume Stats

Current price $118.20 52-week high $129.00
Prev. close $118.00 52-week low $48.15
Day low $116.31 Volume 21,800
Day high $119.60 Avg. volume 14,227
50-day MA $114.16 Dividend yield N/A
200-day MA $97.92 Market Cap 798.20M

Semler Scientific Inc. (SMLR) Company Bio


Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is based in San Jose, California.

SMLR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$118.20$47402.18 42993%

Below please find a table outlining a discounted cash flow forecast for SMLR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Semler Scientific Inc ranked in the 99th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 43204%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for SMLR, they are:

  • SMLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 63.85% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Semler Scientific Inc has a reliance on debt greater than just 0% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%42148%
1%42570%
2%42993%
3%43415%
4%43838%
5%44260%

Want more companies with a valuation profile/forecast similar to that of Semler Scientific Inc? See CHRS, GENN, THC, ACHC, and NVCR.


SMLR Latest News Stream


Event/Time News Detail
Loading, please wait...

SMLR Latest Social Stream


Loading social stream, please wait...

View Full SMLR Social Stream

Latest SMLR News From Around the Web

Below are the latest news stories about Semler Scientific Inc that investors may wish to consider to help them evaluate SMLR as an investment opportunity.

Semler Scientific Inc. (SMLR) Reports Next Week: Wall Street Expects Earnings Growth

Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 26, 2021

Semler to Report Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 2, 2021

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2021, after the close of U.S. financial markets on Monday, August 2, 2021. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior

Yahoo | July 21, 2021

Semler Scientific Inc. (SMLR) Soars 4.2%: Is Further Upside Left in the Stock?

Semler Scientific Inc. (SMLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | July 9, 2021

What Makes Semler Scientific Inc. (SMLR) a New Buy Stock

Semler Scientific Inc. (SMLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | June 25, 2021

Semler to Participate in the Raymond James Human Health Innovation Conference

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that its chief executive officer, Doug Murphy-Chutorian, and chief marketing officer, Dennis Rosenberg, will present a company overview at the Raymond James Human Health Innovation Conference on Tuesday, June 22, at 12:00 pm ET.

Yahoo | June 10, 2021

Read More 'SMLR' Stories Here

SMLR Price Returns

1-mo 1.46%
3-mo 2.78%
6-mo 18.20%
1-year 112.97%
3-year 449.77%
5-year 5,665.85%
YTD 25.74%
2020 95.83%
2019 39.53%
2018 330.00%
2017 451.72%
2016 -43.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8605 seconds.